Stay updated on Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial

Sign up to get notified when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision identifier changed from v3.8.0 to v3.8.1, reflecting a site update rather than a change to the clinical trial record.
    Difference
    0.1%
    Check dated 2026-11-20T15:14:30.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.8.0 instead of v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-30T15:40:24.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    A site-wide NIH notice about replacing the term “Artificial Intelligence” with “Super Intelligence” during a terminology transition appears above the study record.
    Difference
    0.8%
    Check dated 2026-10-23T17:36:59.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The site footer’s revision number changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-16T20:51:10.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-09T20:54:49.000Z thumbnail image
  8. Check
    64 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 was added to the study's history, and the previous revision v3.6.6 was removed.
    Difference
    0.1%
    Check dated 2026-09-18T18:35:43.000Z thumbnail image

Stay in the know with updates to Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.